
|Videos|September 15, 2019
Dr. Castillo on the Use of Venetoclax in Waldenstrom Macroglobulinemia
Author(s)Jorge J. Castillo, MD
Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.
Advertisement
Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
2
Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
3
OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
4
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
5


















































